Advanced in Fibrosarcoma

Dr. Amanda M. Parkes

Hematology Oncology
1515 Holcombe Blvd, 
Houston, TX 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Fibrosarcoma
1515 Holcombe Blvd, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amanda Parkes is a Hematologist Oncology provider in Houston, Texas. Dr. Parkes is rated as an Advanced provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Liposarcoma, Adult Soft Tissue Sarcoma, Bone Tumor, and Undifferentiated Pleomorphic Sarcoma.

Her clinical research consists of co-authoring 29 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in WI
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1515 Holcombe Blvd, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Enrollment Status: Recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Fulvestrant, Adjuvant Therapy
Study Phase: Phase 2
A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Enrollment Status: Recruiting
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Aromatase Inhibitor
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
View 3 Less Clinical Trials

29 Total Publications

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
Journal: Clinical breast cancer
Published: August 14, 2024
Similar Doctors
Distinguished in Fibrosarcoma
Dr. Ravin Ratan
Hematology Oncology | Oncology | Hematology
Distinguished in Fibrosarcoma
Dr. Ravin Ratan
Hematology Oncology | Oncology | Hematology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.6 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ravin Ratan is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Ratan is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, Gamma Knife Radiosurgery, and Bone Marrow Aspiration.

Advanced in Fibrosarcoma
Dr. Vince D. Cataldo
Hematology Oncology | Hematology | Oncology
Advanced in Fibrosarcoma
Dr. Vince D. Cataldo
Hematology Oncology | Hematology | Oncology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-2121
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vince Cataldo is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Cataldo is rated as an Advanced provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Angiosarcoma, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, and Bone Marrow Aspiration. Dr. Cataldo is currently accepting new patients.

Advanced in Fibrosarcoma
Dr. Daniel D. Karp
Hematology Oncology
Advanced in Fibrosarcoma
Dr. Daniel D. Karp
Hematology Oncology
1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Daniel Karp is a Hematologist Oncology provider in Houston, Texas. Dr. Karp is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Thyroid Cancer, Bone Tumor, Rhabdomyosarcoma Embryonal, and Undifferentiated Pleomorphic Sarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Parkes's expertise for a condition
ConditionClose
      View All 14 Advanced Conditions
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile